度伐利尤单抗治疗头颈部鳞状细胞癌患者的安全性与疗效:I/II期扩展队列结果
这项多中心I/II期扩展队列研究纳入62例复发/转移性头颈部鳞状细胞癌患者,每2周静脉给予度伐利尤单抗10 mg/kg,主要终点为安全性。药物相关不良事件发生率为59.7%,III-IV级为9.7%,无药物相关停药或死亡;客观缓解率为6.5%,中位总生存期为8.4个月。
要点
- 度伐利尤单抗10 mg/kg每2周给药,在头颈部鳞状细胞癌中安全性可控。
- 药物相关不良事件发生率59.7%,III-IV级9.7%,无药物相关停药或死亡。
- 客观缓解率6.5%,PD-L1≥25%者为15.0%,<25%者为2.6%。
核心结论
- 度伐利尤单抗在头颈部鳞状细胞癌中的安全性可控,与该研究其他队列一致。
- 在这组经重度既往治疗的患者中观察到早期、持久的缓解,作者认为值得进一步研究;III期单药和联合治疗研究正在进行中。
研究设计与样本
- 多中心I/II期研究的扩展队列,评估复发/转移性头颈部鳞状细胞癌患者的安全性与临床活性。
- 患者每2周静脉接受度伐利尤单抗10 mg/kg,持续12个月或直至确认疾病进展或不可接受的毒性。
- 主要终点为安全性,临床活性为次要终点;62例患者入组并可评估(在数据截止前至少24周接受首剂)。
主要发现
- 中位年龄57岁;40.3%为HPV阳性;32.3%肿瘤细胞PD-L1表达≥25%;62.9%为当前或既往吸烟者;中位既往系统治疗线数为2(范围1-13)。
- 全因不良事件发生率为98.4%;药物相关不良事件发生率为59.7%,其中III-IV级为9.7%;无药物相关停药或死亡。
- 客观缓解率(盲态独立中心审查)为6.5%;PD-L1≥25%者为15.0%,PD-L1<25%者为2.6%。
- 中位起效时间2.7个月(范围1.2-5.5);中位缓解持续时间12.4个月(范围3.5-20.5+)。
- 中位无进展生存期1.4个月;中位总生存期8.4个月;6个月总生存率62%,12个月总生存率38%(PD-L1≥25%者为42%,<25%者为36%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出,在这组经重度既往治疗的患者中观察到的早期、持久缓解值得进一步研究,III期单药和联合治疗研究正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety were reported in urothelial carcinoma, non-small-cell lung cancer (NSCLC), hepatocellular carcinoma (HC) and small-cell lung cancer (SCLC) in a multicenter phase I/II study. Safety and clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) were evaluated in the expansion phase. METHODS: Patients received 10 mg/kg of durvalumab intravenously every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity. The primary objective was safety; clinical activity was a secondary objective. RESULTS: Sixty-two patients were enrolled and evaluable (received first dose ≥24 weeks before data cutoff). Median age was 57 years; 40.3% were human papillomavirus (HPV)-positive; 32.3% had tumour cell PD-L1 expression ≥25%, and 62.9% were current/former smokers. They had a median of 2 prior systemic treatments (range, 1-13). All-causality adverse events (AEs) occurred in 98.4%; drug-related AEs occurred in 59.7% and were grade III-IV in 9.7%. There were no drug-related discontinuations or deaths. Objective response rate (blinded independent central review) was 6.5% (15.0% for PD-L1 ≥25%, 2.6% for <25%). Median time to response was 2.7 months (range, 1.2-5.5); median duration was 12.4 months (range, 3.5-20.5+). Median progression-free survival was 1.4 months; median overall survival (OS) was 8.4 months. OS rate was 62% at 6 months and 38% at 12 months (42% for PD-L1 ≥25%, 36% for <25%). CONCLUSIONS: Durvalumab safety in HNSCC was manageable and consistent with other cohorts of the study. Early, durable responses in these heavily pretreated patients warrant further investigation; phase III monotherapy and combination therapy studies are ongoing. CLINICAL TRIAL REGISTRY: clinicaltrials.gov NCT01693562; MedImmune study 1108.
引用
- Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. Eur J Cancer. 2019. PMID: 30731276. doi:10.1016/j.ejca.2018.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。